Worth Watching Stocks: Qurate Retail, Inc. (NASDAQ:QRTEA), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)


Qurate Retail, Inc. (NASDAQ:QRTEA)

Qurate Retail, Inc. (NASDAQ:QRTEA) represented a move of -1.66 percent or $0.33 per share and closed its previous day trading session at $23.67. 5.26 Million Shares were traded in the last trading session with an Average Volume of 2.79 Million Shares. The stock currently has a Market Capitalization of 10.88 Billion.

Qurate Retail, Inc. operates and owns interests in digital commerce businesses. The company’s business and asset consist of its subsidiaries QVC Inc., HSN Inc., and zulily, llc as well as its interests in ILG and FTD, among other things. Qurate Retail Inc., formerly known as Liberty Interactive Corporation, is based in Colorado, United States.

The stock traded between $20.00 and $29.11 over 1-Year time period showing its price to sales ratio of 0.89. Qurate Retail, Inc. (NASDAQ:QRTEA) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $8.72 and 200-Day Simple Moving Average of $1.46. Its Price to Free Cash Flow is 10.39 and Price to Book of 1.94.

Analyst’s recommended the stock as 2.1 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Qurate Retail, Inc. (NASDAQ:QRTEA) reported its Actual EPS of $0.45/share. The analysts offering Earnings Estimates for the company were believing that Qurate Retail, Inc. could bring EPS of $0.46/share. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus showing an Earnings Surprise of -2.2 Percent.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)

In the last trading session, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) added its value by -2.62% closing at the price of $0.41. The stock currently has market capitalization of 21.63 Million, with average volume of 8.35 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is showing beta of -0.1. This particular value of beta suggests that Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has historically moved -10% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is at $-0.53.

The stock currently has RSI of 52.26. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) topped its 52-week high price of $1.850 on 11/16/17 and 52-Week Low Price of $0.170 on 10/03/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 20.88% and monthly volatility of 23.27% respectively.